Bartholomew J. Naughton

Feasibility and Safety of Systemic rAAV9-h <i>NAGLU</i> Delivery for Treating Mucopolysaccharidosis IIIB: Toxicology, Biodistribution, and Immunological Assessments in Primates

Darren Murrey, Bartholomew J. Naughton, F. Jason Duncan et al. · Human Gene Therapy Clinical Development · 2014 · 88 citations · Full text

Medicine, Pharmacology, Toxicology +15

Blood Genome-Wide Transcriptional Profiles Reflect Broad Molecular Impairments and Strong Blood-Brain Links in Alzheimer's Disease

Bartholomew J. Naughton, F. Jason Duncan, Darren Murrey et al. · Journal of Alzheimer s Disease · 2014 · 61 citations

Life Sciences, Genetics, Neuroscience +17

Dopamine transporter inhibition is necessary for cocaine‐induced increases in dendritic spine density in the nucleus accumbens

Bradley J. Martin, Bartholomew J. Naughton, Keerthi Thirtamara Rajamani et al. · Synapse · 2010 · 37 citations

Life Sciences, Neurobiology, Neuroscience +17

Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma

Christian Ihling, Bartholomew J. Naughton, Yue Zhang et al. · Frontiers in Medicine · 2019 · 30 citations · Full text

Medicine, Oncology, Pathology +17

A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB

Aaron S. Meadows, F. Jason Duncan, Marybeth Camboni et al. · Human Gene Therapy Clinical Development · 2015 · 27 citations · Full text

Pharmacy, Pharmacology, Toxicology +15